Povorcitinib + Placebo

Phase 3Active

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

NonSegmental Vitiligo

Conditions

NonSegmental Vitiligo

Trial Timeline

Nov 27, 2023 → Mar 16, 2027

NCT ID

NCT06113471

About Povorcitinib + Placebo

Povorcitinib + Placebo is a phase 3 stage product being developed by Incyte for NonSegmental Vitiligo. The current trial status is active. This product is registered under clinical trial identifier NCT06113471. Target conditions include NonSegmental Vitiligo.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06516952	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06516965	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06113445	Phase 3	Active	Nov 29, 2023	Feb 24, 2027	NonSegmental Vitiligo
NCT06113471	Phase 3	Active	Nov 27, 2023	Mar 16, 2027	NonSegmental Vitiligo
NCT05936567	Phase 2	Completed	Jul 31, 2023	Oct 9, 2025	Urticaria
NCT05620836	Phase 3	Completed	Feb 22, 2023	Nov 21, 2025	Hidradenitis Suppurativa (HS)
NCT05620823	Phase 3	Completed	Dec 19, 2022	Dec 23, 2025	Hidradenitis Suppurativa (HS)

Competing Products

7 competing products in NonSegmental Vitiligo

See all competitors

Product	Company	Stage	Hype Score
Ritlecitinib + Ritlecitinib + Placebo	Pfizer	Phase 3	76
Ritlecitinib + Placebo	Pfizer	Phase 3	76
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
Ruxolitinib Cream + Vehicle Cream	Incyte	Phase 3	74
INCB054707 + Placebo	Incyte	Phase 2	49
Ruxolitinib Cream	Incyte	Phase 2	49
Povorcitinib + Placebo	Incyte	Phase 3	74

Other Products from Incyte

ruxolitinib creamApproved

Itacitinib + Placebo + Prednisone + MethylprednisolonePhase 3

Povorcitinib + PlaceboPhase 3

Ruxolitinib Cream + Vehicle CreamPhase 3

Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)Phase 3